Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended

Viridian Therapeutics, Inc.\DE

VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.
No serious adverse events, hearing impairment, or hyperglycemia reported in chronic TED patients.
THRIVE Phase 3 trial amended to 5-dose regimen; topline results expected mid-2024.
THRIVE-2 Phase 3 in chronic TED to start Q3 2023; topline results expected by year-end 2024.
IND filed for VRDN-003 and VRDN-001 SC; lead SC candidate selection expected by year-end 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.